British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

Moderna 首席执行官 Stéphane Bancel 在新闻稿中表示：“FDA 批准我们的第二款 [RSV] 产品 mRESVIA，这建立在我们 mRNA 平台的优势和多功能性之上。”“mRESVIA 可保护老年人免受 RSV 感染的严重后果，它是唯一一种采用预填充注射器的 RSV 疫苗，旨在最大限度地提高给药的便利性，节省接种者的时间并降低管理错误的风险。” ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as ...

The Wednesday approval of the GSK vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand ...

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

Preliminary data from GSK shows its RSV vaccine, Arexvy, could help protect people ages 50 to 59 against the virus. Leon Neal/Getty Images/FILE. CNN — ...

GSK said that its vaccine against RSV reduced the risk of developing lower respiratory tract disease by 82.6% in a large trial. Photo: kenzo tribouillard/Agence France-Presse/Getty Images ...

GSK’s vaccines rouse the body’s immunity with an RSV surface protein called the F glycoprotein. Before the virus breaks in and enters the host cell, it exists in a lollipop-shaped prefusion form .

GSK was one of the first companies to announce a phase 3 trial for an RSV vaccine, and last year announced FDA filing acceptance with an FDA decision date of May 3, 2023.